GLP-1 Meds & Our TRT?

Stacking two GLP agents isn't inherently riskier than dose escalation - the side-effect difference depends on which receptors you're adding and what that introduction does to your GI baseline.

The compounding pharmacy supply question is worth thinking about from an inventory angle - the windows where access gets tighter have been real. Building a buffer while you can is a rational response to that uncertainty.

the canadian generic pathway is still a ways out for most people - getting there requires an actual canadian prescriber and pharmacy fill, not just having the product exist. the community tends to update pretty quickly when real availability changes, so keeping an eye on the threads is more reliable than tracking regulatory announcements directly

The compounded pharma FDA approval question is worth getting specifics on - it varies by compound and by state pharmacy regulations. Some providers are uncomfortable prescribing compounded versions even when technically permitted. What was the actual concern raised - efficacy, purity, or something regulatory about their practice?